NORMAL SITUATION

Apoplus

Financial year 2024 · closed on 31/12/2024
Net result
-13,6 k €
-115.9% YoY
Gross margin
-11,8 k €
-21.2% YoY
Equity
207,2 k €
-6.1% YoY

Company — Normal situation.

What does Apoplus do?

Apoplus is a company registered in Belgium.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0667.565.282
Legal form
Private limited company
Contributed capital
18 600,00 €
Latest accounts
31/12/2024
Signals
Solid equityGood liquidity
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 8 financial years

20242023202220212020201920182017
Income statement
Gross margin-11,8 k €-9,7 k €18 k €64 k €17,1 k €10 k €14,9 k €-5,8 k €
EBITDA-12,5 k €-9,8 k €17,9 k €63,9 k €17 k €9,9 k €14,8 k €-5,9 k €
Operating result-12,5 k €-9,8 k €17,9 k €63,9 k €17 k €9,9 k €14,8 k €-5,9 k €
Net result-13,6 k €85 k €78,6 k €54,9 k €11,2 k €4,6 k €11,2 k €-8 k €
Balance sheet
Equity207,2 k €220,8 k €135,8 k €57,2 k €25,2 k €14 k €9,4 k €-1,8 k €
Total assets217,6 k €289,5 k €235,4 k €202,9 k €177,9 k €180,3 k €178,9 k €167,4 k €
Cash5,1 k €9,6 k €390,3 €32,1 k €4,5 k €9,5 k €9,1 k €1,3 k €
Debts10,4 k €66,7 k €96 k €142,7 k €150,9 k €160,8 k €166,9 k €167,9 k €
Governance

Board of directors

Seen on filing of 31/12/2024 · 4 active · 7 ended

Active mandates

Geert Reyniers

Director · since 15 avril 2024 · until 13 juin 2030

Active
Anke Vloemans

Director · since 08 décembre 2016 · until 15 avril 2024

Active
ORTEGAWYNTER

Director · since 08 décembre 2016 · until 15 avril 2024 · 0501.597.490

Represented by Carlos Ortega Saez

Active
TM Pharma

Director · since 08 décembre 2016 · until 15 avril 2024 · 0881.130.182

Represented by Mieke Raemdonck

Active

Ended mandates

Anke Vloemand

Director · since 08 décembre 2016

Ended
Anke Vloemans

Director · since 08 décembre 2016

Ended
Anke Vloemans

Manager · since 08 décembre 2016

Ended
ORTEGAWYNTER

Director · since 08 décembre 2016 · 0501.597.490

Represented by Carlos Ortega Saez

Ended
Annual accounts

Full financial information

202420232022202120202019
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202401/01/202301/01/202201/01/202101/01/202001/01/2019
Closing of the financial year31/12/202431/12/202331/12/202231/12/202131/12/202031/12/2019
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date23/06/202512/04/202427/07/202315/07/202229/06/202106/07/2020
General meeting12/06/202527/03/202419/06/202320/06/202221/06/202122/06/2020
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

8 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202412/06/202523/06/2025FrenchPDF
Abridged model31/12/202327/03/202412/04/2024DutchPDF
Abridged model31/12/202219/06/202327/07/2023DutchPDF
Abridged model31/12/202120/06/202215/07/2022DutchPDF
Abridged model31/12/202021/06/202129/06/2021DutchPDF
Abridged model31/12/201922/06/202006/07/2020DutchPDF
Abridged model31/12/201817/06/201918/06/2019DutchPDF
Abridged model31/12/201718/06/201819/06/2018DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 4 active · 7 ended

Active mandates

Geert Reyniers

Director · since 15 avril 2024 · until 13 juin 2030

Active
Anke Vloemans

Director · since 08 décembre 2016 · until 15 avril 2024

Active
ORTEGAWYNTER

Director · since 08 décembre 2016 · until 15 avril 2024 · 0501.597.490

Represented by Carlos Ortega Saez

Active
TM Pharma

Director · since 08 décembre 2016 · until 15 avril 2024 · 0881.130.182

Represented by Mieke Raemdonck

Active

Ended mandates

Anke Vloemand

Director · since 08 décembre 2016

Ended
Anke Vloemans

Director · since 08 décembre 2016

Ended
Anke Vloemans

Manager · since 08 décembre 2016

Ended
ORTEGAWYNTER

Director · since 08 décembre 2016 · 0501.597.490

Represented by Carlos Ortega Saez

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Restructuring24/06/2025
    Opération assimilée à la fusion par absorption par la société coopérative
    PDF
  • Restructuring28/05/2025
    KAPITAAL - AANDELEN - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring11/04/2025
    Projet de fusion
    PDF
  • Restructuring11/03/2025
    Projet de fusion
    PDF
  • Other13/02/2025
    TOEKENNING VAN VOLMACHTEN TOT BANKVERRICHTINGEN
    PDF
  • Registered office04/07/2024
    Verplaatsing van de zetel van de vennootschap naar het Brussel
    PDF
  • Mandates10/06/2024
    Ontslag en benoeming bestuurders, benoeming commissaris - Verplaatsing
    PDF
  • Mandates17/10/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - WIJZIGING RECHTSVORM - DOEL - ONTSLAGEN - BENOEMINGEN
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2024
    Annual accounts 2024-13,6 k €
  2. 2023
    Annual accounts 202385 k €
  3. 2022
    Annual accounts 202278,6 k €
  4. 2021
    Annual accounts 202154,9 k €
  5. 2020
    Annual accounts 202011,2 k €
  6. 2019
    Annual accounts 20194,6 k €
  7. 2018
    Annual accounts 201811,2 k €
  8. 2017
    Annual accounts 2017-8 k €